Butterfly Network (BFLY) Q4 2024: 35% Revenue Growth Anchors Transition to Scalable Digital Ultrasound Ecosystem
Butterfly Network delivered its highest quarterly revenue ever with 35% year-over-year growth, driven by strong adoption of its next-generation IQ3 ultrasound device and expanding international footprint. The company’s strategic shift toward integrated AI-powered ultrasound solutions and home care pilots signal a broadening market opportunity beyond traditional point-of-care ultrasound. Capital raised early 2025 reinforces a clear path to cash flow independence while enabling investment in growth initiatives.
Summary
- Core Business Momentum: Butterfly’s IQ3 device and software ecosystem are driving sustained revenue expansion and improving gross margins.
- Emerging Growth Channels: Home care pilots and Octave partnerships are laying groundwork for new revenue streams beyond hospital settings.
- Strategic Capital Deployment: Recent $81.7 million raise supports scaling initiatives while maintaining disciplined cost management.
Business Overview
Butterfly Network specializes in portable, semiconductor-based ultrasound devices combined with AI-enabled software to democratize medical imaging. Its primary revenue streams include sales of handheld ultrasound probes, enterprise software subscriptions, and emerging services such as home care ultrasound management. The company’s key segments encompass core point-of-care ultrasound hardware and software, AI application partnerships under Butterfly Garden, and non-competitive market chip technology through its Octave subsidiary.
Performance Analysis
Butterfly recorded $22.4 million in revenue for Q4 2024, marking a 35% increase from $16.5 million a year earlier. Growth was fueled by a 45% jump in product revenue to $14.7 million, reflecting a 22% increase in units sold and higher average selling prices (ASP) driven by the IQ3 device. Software and other services revenue also grew 20% year-over-year to $7.6 million, though its mix declined to 34% of total revenue as product sales outpaced software growth. U.S. revenue rose 32% to $14.5 million, while international sales increased 19% to $5.5 million, demonstrating successful geographic expansion.
Gross profit improved dramatically to $13.7 million from a prior year gross loss, lifting gross margin to 61.4% from negative 75.9%. This margin expansion was primarily attributable to higher ASPs and improved software margins, partially offset by increased production and warranty costs on the IQ3. Operating expenses declined 9% to $31 million due to prior restructuring and ongoing cost rationalization efforts. Adjusted EBITDA loss narrowed to $9.1 million from $15.7 million, reflecting both revenue growth and operating efficiencies. The company ended 2024 with $92.8 million in cash, bolstered by a subsequent $81.7 million capital raise in January 2025, providing runway toward cash flow breakeven.
- Revenue Drivers: IQ3 accounted for 50% of 2024 sales and 58% of product revenue, attracting new users and upgrades from existing customers.
- Margin Improvement: Gross margin recovery reflects pricing power and operational leverage despite higher amortization and warranty expenses.
- Cost Discipline: Operating expense reductions and infrastructure rightsizing contributed to significant EBITDA loss improvement.
Overall, Butterfly’s financial results underscore successful execution of its five-year plan launched in early 2024, positioning the company for scalable growth fueled by innovative hardware, AI software, and expanding service offerings.
Executive Commentary
"With 25% topline growth, high-impact product launches and key milestones achieved, we completed a strong first year of the five-year plan and put programs in place to accelerate growth across our core point-of-care ultrasound business, as well as Octiv™ and Butterfly HomeCare."
Joe DeVivo, CEO
"The 42% improvement in adjusted EBITDA loss was driven by higher revenue, cost reductions and efficiencies, which led to lower payroll consulting and other outside services."
Heather, CFO
Strategic Positioning
1. Scaling Core Point-of-Care Ultrasound with IQ3
The IQ3 device has become the flagship product, representing half of 2024 sales and driving higher ASPs. Butterfly’s strategy emphasizes expanding hospital penetration beyond traditional wellness and personal use, targeting intensive care, emergency rooms, anesthesiology, and cardiology departments. Enterprise software sales bundled with hardware are central to deepening multi-departmental and full enterprise customer relationships.
2. Expanding Butterfly Garden AI Ecosystem
Butterfly Garden now includes 21 AI development partners, with four new additions in Q4 including the first veterinary AI app. Six partners are expected to commercialize products in 2025, five seeking FDA clearance. These AI applications aim to simplify ultrasound acquisition and interpretation, enhancing user experience and creating recurring revenue opportunities through app sales within Butterfly’s ecosystem.
3. Commercializing Chip Technology via Octave
Octave, Butterfly’s wholly owned subsidiary, signed three new partners in Q4, including Sonic Insights for liver disease assessment, and others in neuroscience and generative AI hardware. These partnerships broaden the use of Butterfly’s semiconductor ultrasound technology in non-competitive markets, with anticipated revenue contributions starting in the second half of 2025.
4. Pioneering Home Care Ultrasound Services
Butterfly HomeCare launched a pilot with a major Medicare Advantage provider, training nurse practitioners in AI-guided lung ultrasound to monitor congestive heart failure patients in long-term care. Early results show no hospital readmissions and timely interventions, validating the model’s potential to reduce healthcare costs. A proof of concept with MyPlace Health demonstrated identification of undiagnosed conditions and reimbursement risk scoring, positioning Butterfly to expand into additional PACE organizations.
5. Strategic Capital Raise and Operational Discipline
The $81.7 million follow-on offering completed in January 2025 strengthens Butterfly’s balance sheet, enabling continued investment in growth initiatives without compromising fiscal discipline. Management emphasizes maintaining a clear path to cash flow independence while selectively funding programs that expand market reach and innovation.
Key Considerations
Butterfly’s fourth quarter results reflect a successful execution of its multi-pronged growth strategy, combining hardware innovation, AI software integration, and service expansion. The company is navigating a transition from device sales to a broader digital health platform with multiple revenue levers.
Key Considerations:
- Product Leadership: IQ3’s market acceptance validates Butterfly’s semiconductor ultrasound technology and supports pricing power.
- Market Diversification: Growth in international markets and new channels like home care mitigate concentration risk and open new avenues.
- AI Ecosystem Development: Butterfly Garden partnerships enhance user value and create potential for recurring software revenue.
- Capital Allocation: Recent fundraising provides flexibility but underscores the importance of disciplined investment amid ongoing losses.
- Operational Execution: Cost reductions and infrastructure optimization have improved profitability metrics but sustaining this while scaling is critical.
Risks
Butterfly faces execution risks in scaling new business lines such as home care and Octave partnerships, where revenue timing and adoption remain uncertain. Competitive pressures in the point-of-care ultrasound market and regulatory challenges, including the pending EU RoHS exemption review, could impact operations. The company’s path to profitability depends on sustained revenue growth and cost control amid ongoing investment in innovation.
Forward Outlook
For Q1 2025, Butterfly expects revenue between $20 million and $23 million, reflecting typical seasonal softness in hospital deal closures. Adjusted EBITDA loss is projected between $9 million and $11 million due to payroll tax resets and event-related expenses.
- Full-year 2025 revenue guidance is $96 million to $100 million, approximately 20% growth over 2024.
- Adjusted EBITDA loss guidance is $37 million to $42 million, reflecting continued investment balanced with operational efficiencies.
Management’s guidance excludes incremental revenue from new Octave partnerships and home care commercialization, emphasizing a conservative approach aligned with current visibility.
Takeaways
Butterfly Network is executing a strategic transformation from a handheld ultrasound device company to a digital health platform integrating AI, software, and services. The strong IQ3 adoption and margin recovery validate core technology leadership, while emerging initiatives in home care and AI partnerships offer substantial optionality for future growth. The recent capital raise provides a runway to scale these opportunities without sacrificing financial discipline. Investors should monitor execution on scaling new revenue streams and regulatory developments that could influence market access.
- Core Business Validation: IQ3’s commercial success and improved margins indicate Butterfly’s semiconductor ultrasound technology has achieved competitive parity, unlocking hospital channels and driving revenue expansion.
- Strategic Growth Diversification: Butterfly Garden AI apps and Octave partnerships represent strategic bets on software and chip technology commercialization beyond traditional ultrasound, potentially expanding addressable markets.
- Execution Focus: The company’s disciplined cost management and capital raise position it well for scaling, but execution risks remain in converting pilots to commercial revenue and navigating regulatory uncertainties.
Conclusion
Butterfly Network’s Q4 2024 results demonstrate a pivotal step in its five-year plan, combining robust core product growth with promising new initiatives. The company’s ability to leverage its AI-driven ultrasound platform and expand into home care and chip technology markets will be critical to achieving long-term revenue and profitability targets.
Industry Read-Through
Butterfly’s progress underscores the growing importance of semiconductor-based ultrasound devices combined with AI to disrupt traditional medical imaging. The integration of portable hardware, cloud software, and AI applications reflects a broader industry shift toward digital, accessible diagnostic tools. Its success in scaling home care ultrasound services offers a blueprint for other companies seeking to extend imaging beyond hospital walls. Regulatory developments like the EU RoHS exemption process will be closely watched as they may impact device manufacturing and market access across the medtech sector.